fig2

Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

Figure 2. Exploring MAGEA3 expression in mice CRC and human CRC samples. (A) The mRNA level of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues in untreated mice; (B) The mRNA level of MAGEA3 in different human CRC cell lines HCT116, Caco-2, and HT29, compared to normal colon epithelial cell line FHC; (C and D) Images and quantification of Western blot of MAGEA3 in tumor and peri-tumor colon tissues from AOM/DSS-treated mice compared to colon tissues from untreated mice; (E and F) Representative images and quantification of immunohistochemistry staining of MAGEA3 in tumor and peri-tumor tissues of human CRC (scale bar: 100 μm). ns: no significance, *P < 0.05, **P < 0.01, ****P < 0.0001. CRC: colorectal cancer; AOM: azoxymethane; DSS: dextran sulfate sodium.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/